

Real-World Outcomes of DMEK: A Prospective Dutch registry study



SURYAN L. DUNKER, MANON H.J. VELDMAN, BJORN WINKENS, FRANK J.H.M. VAN DEN BIGGELAAR, RUDY M.M.A. NUIJTS, PIETER JAN KRUIT, AND MOR M. DICKMAN, ON BEHALF OF THE DUTCH CORNEA CONSORTIUM

- **PURPOSE:** This study analyzed real-world practice patterns, graft survival, and outcomes of Descemet membrane endothelial keratoplasty (DMEK) in the Netherlands.
- **DESIGN:** Population-based interventional clinical study.
- **METHODS:** In this prospective registry study, all consecutive primary DMEK procedures registered in the Netherlands Organ Transplant Registry were identified. Short-term graft survival and outcomes of primary transplants for Fuchs' endothelial dystrophy (FED) were analyzed using Kaplan-Meier survival curves with log-rank test and Cox regression. Linear mixed model analyses were used for best spectacle-corrected visual acuity (BSCVA), spherical equivalent, hyperopic shift, and endothelial cell density.
- **RESULTS:** 752 DMEKs were identified between 2011 and 2018. In 90% of cases, the indication for DMEK was FED. Graft survival measured 87% at 3 months, 85% at 6 months, 85% at 1 year, and 78% at 2 years. DMEK procedures after 2015 showed better survival compared to previous years (Hazard ratio = 0.4; $P < .001$). Baseline BSCVA in primary transplants with FED measured on average 0.45 logarithm of the minimum angle of resolution (logMAR) (95% confidence interval [CI], 0.41-0.49), and significantly improved (overall $P < .001$) to 0.17 logMAR (95% CI, 0.14-0.21) at 3 months, 0.15 logMAR (95% CI, 0.11-0.18) at 6 months, 0.12 logMAR (95% CI, 0.08-0.16) at 1 year, and 0.08 (95% CI, 0.05-0.12) at 2 years. At 3 months, a hyperopic shift of +0.36 diopters ($P < .001$) was observed and endothelial cell loss measured 33%.
- **CONCLUSION:** Our findings provide real-world support that DMEK is an effective treatment for FED with respect

to vision restoration, inducing a small hyperopic shift with an acceptable endothelial cell loss. Graft survival improved over time, suggesting a learning curve on a national level. (Am J Ophthalmol 2021;222:218–225. © 2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

NATIONAL QUALITY REGISTRIES ARE INCREASINGLY recognized in recent years as a valuable tool for improving healthcare via the use of real-world data.¹ The primary attribute that distinguishes “real-world” evidence is related to the context in which the evidence is gathered in other words, in clinical care settings. Key to understanding the usefulness of real-world evidence is an appreciation of its potential for complementing the knowledge gained from traditional clinical trials, whose well-known limitations make it difficult to generalize findings to larger, more inclusive populations of patients and settings that reflect actual use in practice.²

Much of our knowledge on the outcomes of corneal transplantation originates from such registries. Using the Netherlands Organ Transplant Registry (NOTR), our group previously reported on the long-term real-world outcomes of penetrating keratoplasty (PK) and Descemet stripping automated endothelial keratoplasty (DSAEK).^{3,4}

Descemet membrane endothelial keratoplasty (DMEK), the latest iteration in endothelial keratoplasty (EK), is reported to achieve excellent visual outcomes with relatively low complication rates in specialized centers.⁵ However, little is known about the real-world outcomes of DMEK.

In the current study, we retrospectively analyze prospectively collected NOTR data and report the real-world outcomes of DMEK in the Netherlands in terms of graft survival, longitudinal trends in visual acuity, refraction, endothelial cell density (ECD), and complications.

METHODS

- **GRAFT REGISTRY AND DATA COLLECTION:** Data for this multicenter prospective registry study was obtained from the NOTR, a prospective national database founded

Accepted for publication Jun 12, 2020.

From the University Eye Clinic (S.L.D., M.H.J.V., F.J.H.M.vdB., R.M.M.A.N., M.M.D.), Maastricht University Medical Center, Maastricht, the Netherlands. Department of Ophthalmology (M.H.J.V.), Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam Public Health, Amsterdam, the Netherlands. Department of Methodology and Statistics (B.W.), Faculty of Health, Medicine and Life Sciences, Care and Public Health Research Institute, Maastricht University, Maastricht, Netherlands. Department of Ophthalmology (R.M.M.A.N.), Zuyderland Medical Center, Heerlen, the Netherlands; and the Euro Tissue Bank - Bio Implant Service (ETB-BISLIFE) (P.J.K.), Leiden, the Netherlands.

Inquiries to Suryan L. Dunker, University Eye Clinic, Maastricht University Medical Center, Postbus, 6202 AZ Maastricht, the Netherlands; e-mail: suryan.dunker@mumc.nl

by the Netherlands Transplantation Foundation (Nederlandse Transplantatie Stichting [NTS], <https://www.transplantatiestichting.nl/over-de-nts>). In the Netherlands, donor corneas are centrally allocated and registered in NOTR. Therefore, data regarding graft survival is complete and independent of center/surgeon reporting. Using NOTR, the NTS prospectively captures data related to the recipient, donor, eye bank processing, and surgical procedure of all corneal transplantations performed in the Netherlands except for one clinic. Corneal surgeons prospectively complete relevant follow-up data at predefined time points using a standardized electronic data capture system. The evaluating factors defined in the prospective study protocol include donor characteristics: age, gender, and ECD; recipient characteristics: age, gender, and indication for transplantation; surgery characteristics: date of surgery, transplant type, previous corneal transplants, baseline visual acuity and refraction, complications, and lens status; and postoperative data: date of follow-up, graft status, visual acuity, refraction, ECD, adverse events, interventions, graft failure specification and date, last known follow-up date, lost to follow up status. Data collection continues until graft failure or loss to follow-up. For this study, the NOTR steering group provided institutional review board approval for data extraction and analysis. Informed consent was obtained from all patients to participate in the registry and for the use of data for research. The study adhered to the tenants of the Declaration of Helsinki and Dutch legislation.

- **POPULATION:** DMEK tissue was provided by two eye banks. Ten corneal clinics registered DMEK in NOTR. In line with institutional review board approval, information on center and surgeons was not made available. The first DMEK surgery registered in NOTR was performed on October 5, 2011. The study cohort included all consecutive DMEK procedures until May 31, 2018. All patients received a tapered topical corticosteroid regimen during the first six months after surgery, followed by low dose maintenance thereafter.

- **OUTCOME MEASUREMENTS:** The primary outcome measure was graft survival. Graft failure was reported by the corneal surgeon as defined by the coding guidelines provided by NOTR, or identified in case of a subsequent corneal transplantation in the same eye. Graft failure occurring within three months of transplantation was defined as early graft failure (EGF). Secondary outcomes were: best spectacle-corrected visual acuity (BSCVA), ECD, spherical equivalent (SE), hyperopic shift, and rebubbling. Snellen acuity was converted to the logarithm of the minimum angle of resolution (logMAR) for statistical analyses. Spherical equivalent was defined as the sum of the spherical value and half of the cylindrical value. Refractive shift was defined as the difference in postoperative SE and preoperative SE. Refractive shift was calculated for sin-

gle DMEK as data on target refraction was not available in triple DMEK.

- **STATISTICAL ANALYSIS:** Statistical analyses were performed using IBM SPSS Statistics for Windows, version 24.0 (IBM Corp., Armonk, N.Y., USA). Baseline characteristics were reported as frequencies with percentages or mean \pm SD. The number of transplants over time was tested using the chi-squared goodness-of-fit test.

Graft survival and longitudinal trends in BSCVA, ECD, and SE were calculated for all DMEK procedures that had Fuchs' endothelial dystrophy (FED) as indication excluding cases with anterior chamber intraocular lenses, and unknown lens status. Outcomes are reported over two years after surgery, due to a very low number of events (i.e. failed grafts), and limited number of cases with longer follow-up. In case both eyes of the same patient were operated or repeat transplant was performed, only the first transplant per patient was included in the primary analyses. This was done to prevent bias related to correlated measurements within the same patient or eye. Death-censored graft survival was assessed using Kaplan-Meier survival curves with log-rank test and univariable Cox regression analysis with transplant year (five categories: before 2015, 2015, 2016, 2017, 2018) as an explanatory factor. Cox regression analysis was performed over the first six months postoperatively, since the vast majority of events (i.e. graft failure) occurred during the period. Proportional hazard assumption was checked using the log(-log) survival function plot. Sensitivity analyses including all transplants were also performed. Linear mixed models (LMM) were fitted to investigate the longitudinal trend in BSCVA, ECD, SE, and hyperopic shift, where time, transplant year, ocular comorbidity, and lens status were included as fixed factors and an unstructured covariance structure was used for the repeated measures (preoperative recipient or donor, 3, 6, and 12 months). LMM assume missing at random (MAR), i.e. missingness may depend on observed variables, which should then be incorporated in the model. The differences in characteristics in patients with missing data were compared to patients without missing data (no significant differences found). Cases that developed graft failure were excluded from the analysis of BSCVA, ECD, and SE. Estimated marginal means (EMM) were reported, and changes between different time-points were tested. *P* values $\leq .05$ were considered statistically significant.

RESULTS

- **PRACTICE PATTERNS:** In total, 752 DMEK procedures were registered in NOTR between January 1st, 2011 until May 31st, 2018. The proportion of DMEK procedures increased significantly over time (*P* < .001) (Figure 1). Until 2015, 104 DMEK procedures were performed. The




FIGURE 1. Real-world outcomes of Descemet membrane endothelial keratoplasty (DMEK), a prospective Dutch registry study. The figure shows all consecutively performed DMEK procedures (blue diamonds) in the Netherlands until 2017. Descemet stripping automated endothelial keratoplasty (DSAEK, red circles) and penetrating keratoplasty (PK, green triangles) are shown for comparison. The proportion of DMEK procedures increased significantly over time ($P < 0.001$). The year 2016 marks a major turning point, showing a 395% increase in the number of procedures performed compared to 2015.

greatest increase occurred between 2015 and 2016 ($n = 43$ vs. $n = 213$, respectively; $P < .001$). In contrast, the proportion of Descemet stripping automated endothelial keratoplasty (DSAEK) and penetrating keratoplasty (PK) procedures decreased since 2015 (2015 vs. 2017: $n = 735$ vs. $n = 527$, respectively; $P < .001$; DSAEK $n = 360$ vs. $n = 248$, respectively; $P < .001$, PK). In 2017, the number of DMEK procedures surpassed PK for the first time. In the first half of 2018, slightly more DMEK procedures were performed compared to DSAEK (171 vs. 166, respectively).

Recipient and donor demographics, indication for surgery, and surgical procedure are given in Table 1. The leading indication was FED (90%), followed by graft failure (5%), and pseudophakic bullous keratopathy (3%). 77% of DMEK procedures were performed in pseudophakic eyes, 6% in phakic eyes, and 7% were combined with cataract extraction and intraocular lens placement (triple DMEK).

• GRAFT SURVIVAL: A total of 468 DMEK procedures were available for graft survival analysis after excluding fellow eyes ($n = 125$), indications other than FED including regrafts ($n = 58$), anterior chamber intraocular lenses or unknown lens status ($n = 53$), and missing data ($n = 48$). At three, six, twelve, and 24 months 30, 98, 244, and 369 cases were censored, respectively. Overall graft survival measured 87% at three months, 85% at six months, 85% at 1 year, and 78% at two years (Figure 2). A single graft failure was registered after two years. In <2015, 2015, 2016, 2017, and 2018, 41, 34, 179, 175,

TABLE 1. Real-World Outcomes of DMEK^a

Parameter	Mean \pm SD or %
Recipient	
Primary disease, % FED; PBK; graft failure	90; 3; 5
Central corneal thickness, μm	647 \pm 82
Age, yrs	71 \pm 9
% Males	47
% Right eyes undergoing surgery	51
Donor	
Age, yrs	72 \pm 8
% Males	63
Surgery	
% Surgeries in the pseudophakic eye	77
% Surgeries in the phakic eye	6
% Triple procedures	7
% Surgeries in eyes with PAC or other	10

DMEK = Descemet membrane endothelial keratoplasty; FED = Fuchs' endothelial dystrophy; PAC = pseudophakic, anterior chamber; PBK = pseudophakic bullous keratopathy; SD = standard deviation.

^aTable shows baseline patient, donor, and surgery characteristics of all consecutive DMEK surgeries registered in Netherlands Organ Transplant Registry until May 31st, 2018.

and 39 cases were available for analysis, respectively. Graft survival was similar for <2015 and 2015 ($P = .85$), as well as for 2016, 2017 and 2018 (all $P \geq .26$). When combined, transplants performed between 2016 and 2018 showed higher survival probability compared to earlier transplants (Hazard ratio [HR] = 0.4; 95% confidence interval [CI], 0.25-0.63; $P < .001$) (Figure 3). The database captured two graft rejection episodes. In both cases, patients did not have known risk factors for graft rejection and were treated according to standard protocol prior to graft rejection. Graft rejection was reversible in both cases.

• VISUAL AND REFRACTIVE OUTCOMES: Mean BSCVA during a follow-up period of one year is shown in Figure 4. BSCVA measured 0.45 logMAR (95% CI, 0.41-0.49) ($n = 442$) preoperatively and significantly improved (overall $P < .001$) to 0.17 logMAR (95% CI, 0.14-0.21) ($n = 380$) at three months, 0.15 logMAR (95% CI, 0.11-0.18) ($n = 306$) at six months, 0.12 logMAR (95% CI, 0.08-0.16) ($n = 214$) at one year, and 0.08 logMAR (95% CI, 0.05-0.12) ($n = 45$) at two years. The cumulative percentage of eyes reaching various best spectacle-corrected Snellen acuities is given in Figure 5. Twelve months after DMEK, 67% and 28% of eyes reached $\geq 20/25$ and $\geq 20/20$ Snellen BSCVA, respectively.

A statistically significant hyperopic shift was observed three months after DMEK alone (0.36 D; 95% CI, [0.20-0.51], $P < .001$), which stabilized thereafter. Spherical equivalents values for single DMEK are given in Table 2.




FIGURE 2. Real-world outcomes of Descemet membrane endothelial keratoplasty (DMEK). The figure shows the overall graft survival of primary DMEK grafts for Fuchs' endothelial dystrophy throughout 2 years of follow-up (n = 468 at time 0). Graft survival measured 85% after 1 year (censored cases, n = 244) and 78% after 2 years (censored cases, n = 369).




FIGURE 3. Real-world outcomes of Descemet membrane endothelial keratoplasty (DMEK). Evolution of graft survival over time of primary DMEK for Fuchs' endothelial dystrophy. Graft survival was significantly better in procedures performed since 2016 compared to earlier procedures (hazard ratio = 0.4; $P < 0.001$). Procedures performed <2015, n = 41; 2015, n = 34; 2016, n = 179; 2017, n = 175; and 2018, n = 39 (excluding censoring).

- **ENDOTHELIAL CELL DENSITY:** Donor and postoperative ECD are given in Table 2. Donor ECD measured 2706 cells/mm² (95% CI, 2670-2741), decreasing to 1799 cells/mm² (95% CI, 1729-1869), $P < .001$ (33% cell loss) at three months and stabilizing thereafter.

- **REBUBBLING:** Rebubbling was the most common complication. In the entire cohort, 144 rebubbings were registered, corresponding to a 19% rebubbling rate. Subsequent rebubbling was performed in 3%, and a single case underwent a third rebubbling. Rebubbling rate measured 11% before 2015, 14% in 2015, 25% in 2016, 20% in 2017, and 14% in 2018. In triple DMEK, rebubbling rate did not differ significantly from single DMEK (odds ratio = 0.87; 95% CI, [0.41-1.85]; $P = .72$).

Sensitivity analyses, including all transplants, did not appreciably change the outcomes. For the primary outcome measure, graft survival measured for sensitivity vs. primary analysis 87% vs. 87% at three months, 86% vs. 85% at six months, 86% vs. 85% at one year, and 77% vs. 78% two years after surgery, respectively.

- **DISCUSSION:** This registry study analyzed the practice patterns and outcomes of DMEK in the Netherlands. To the best of our knowledge, this is the first national registry study to report the real-world outcomes of DMEK.

DMEK was introduced in the Netherlands in 2002.⁶ Between 2002 and 2010, the procedure was performed in a single private clinic that does not register in NOTR. From 2011 until 2015, a total of 104 DMEK procedures

were recorded in NOTR. In contrast, 213 DMEK procedures were registered in 2016 alone, marking a major turning point in the uptake of the technique. Concurrently, the number of DSAEK procedures decreased since 2016. In the first half of 2018, marginally more DMEK procedures were recorded compared to DSAEK.

In our cohort, graft survival measured 85% twelve months after DMEK. Almost all failures occurred during the first three months after surgery. This figure is lower compared to the 92% - 100% graft survival rate reported in the Ophthalmic Technology Assessment (OTA) by the American Academy of Ophthalmology.⁷ While the current registry study captures data from a heterogeneous group of medical centers, including high- and low-volume as well as specialized and non-specialized centers, most of the data in the OTA arises from highly specialized centers, limiting generalizability.

DMEK survival in this NOTR cohort was also lower compared to the 94% two-year graft survival rate after DSAEK in NOTR.³ The short-term graft survival in DMEK improved significantly over time, which suggests a learning curve on a national level for a technically challenging procedure. Indeed, the time frame in our study includes the learning curve of multiple surgeons. Another explanation for improving graft survival over time is standardization of the surgical technique during the study period. We recently reported that the survival and functional outcomes of repeated DSAEK grafts are significantly worse than primary DSAEK.⁴ This is important as the




FIGURE 4. Real-world outcomes of Descemet membrane endothelial keratoplasty (DMEK). Estimated marginal means best spectacle-corrected visual acuity during a follow-up period of 2 years for primary DMEK for Fuchs' endothelial dystrophy (blue diamonds). best spectacle-corrected visual acuity improved significantly after DMEK and was superior to DSAEK and PK. However, baseline differences among the techniques make a direct comparison difficult. Baseline, n = 442; 3 months, n = 380; 6 months, n = 306; 12 months, n = 214; 24 months, n = 45. *BSCVA in DSAEK (purple circles) and PK (green triangles) in eyes with Fuchs' endothelial dystrophy of a previous NOTR study are shown for comparison.³ DMEK = Descemet membrane endothelial keratoplasty; DSAEK = Descemet stripping automated endothelial keratoplasty; LogMAR = logarithm of the minimum angle of resolution; NOTR = the Netherlands Organ Transplantation Registry; PK = penetrating keratoplasty.




FIGURE 5. Real-world outcomes of Descemet membrane endothelial keratoplasty (DMEK). Bar graph shows the best spectacle-corrected Snellen visual acuity in primary DMEK for Fuchs' endothelial dystrophy before surgery (n = 442), and 3 months (n = 380), 6 months (n = 306), 12 months (n = 214), and 24 months (n = 45) after surgery. Twelve months after DMEK, 67% and 28% of eyes reached ≥20/25 and ≥20/20 Snellen, respectively.

current study found higher DMEK graft failure rate during the early years (<2016). If repeat-DMEK is also significantly worse compared to primary DMEK, it would underscore the impact of introducing DMEK on a national level.

With the introduction of DMEK, anatomic restoration of the cornea became possible, avoiding interface irregularities and potentially improving vision. In our study,

BSCVA improved from 0.45 logMAR before surgery to 0.12 logMAR one year after surgery. The postoperative BSCVA in DMEK is better compared to PK and DSAEK for FED in NOTR (0.39 logMAR and 0.29 logMAR at one year, respectively).³ However, PK and DSAEK show worse BSCVA at baseline compared to DMEK (0.9 logMAR and 0.68 logMAR, respectively). The reason for

TABLE 2. Real-World Outcomes of DMEK^a

Follow-up	BSCVA	SE	ECD
	EMM LogMAR [95% CI] (n)	EMM Diopter [95% CI] (n) ^b	EMM cells/mm ² [95% CI] (n)
Baseline or donor	0.45 [0.41-0.49] (442)	-0.49 [-0.75 to -0.23] (355)	2706 [2670-2741] (441)
3 months	0.17 [0.14-0.21] (380)	-0.13 [-0.39 to 0.12] (309)	1799 [1729-1869] (182)
6 months	0.15 [0.11-0.18] (306)	-0.20 [-0.46 to 0.06] (212)	1762 [1689-1836] (168)
1 year	0.12 [0.08-0.16] (214)	-0.20 [-0.46 to 0.07] (149)	1744 [1668-1820] (138)
2 years	0.08 [0.05-0.12] (45)	-0.07 [-0.44 to 0.30] (34)	1670 [1495-1844] (23)

BSCVA = Best spectacle-corrected visual acuity; CI = confidence interval; DMEK = Descemet membrane endothelial keratoplasty; ECD = Endothelial cell density; EMM = Linear mixed-model estimated marginal mean; LogMAR = logarithm of the minimum angle of resolution; SE = spherical equivalent.

^aTable shows BSCVA, SE, and ECD in eyes with Fuchs' endothelial dystrophy at 3, 6, 12, and 24 months after DMEK.

^bDMEK combined with cataract extraction and intraocular lens implantation were excluded.

this difference in baseline BSCVA may be two-fold. First, an allocation bias of eyes with better prognosis to novel techniques. Second, a lower threshold for surgical intervention at earlier stages of visual disability.⁸

Historically, the core outcome parameter for corneal transplantation shifted from graft survival in the era of PK to visual acuity with EK. However, differences in VA in modern EK procedures are small, and patients routinely undergo surgery for symptoms such as reduced contrast sensitivity or glare disability irrespectively of VA.⁹⁻¹¹ Patient-reported outcome measures have been developed to capture this information.^{12,13} However, these are currently not part of the standard evaluation in many centers, and as such are not yet recorded in NOTR.

Randomized controlled trials offer a less biased comparison between treatment modalities under controlled circumstances. However, they are costly and under certain circumstances no longer ethical to perform. In contrast, registries provide a low-cost window into routine clinical care (real-world). The strong internal validity of RCTs goes inevitably at the expense of generalizability, while registries suffer from low internal validity. Both study designs can complement each other. Registries can provide external validity to RCTs with restrictive eligibility criteria. In the current study, BSCVA is comparable to two recent RCTs comparing DMEK and ultrathin DSAEK.^{14,15} A novel study design, the randomized registry study, combines the strength of randomization with the advantages of registries and may provide a cost-effective solution for increasingly more expensive health care systems.¹

The hyperopic shift after DSAEK is primarily thought to result from the meniscus-shaped profile of the donor lenticule.¹⁶ In DMEK, the hyperopic shift is likely due to curvature changes in response to corneal hydration status.¹⁷ In the current cohort, a hyperopic shift of +0.36 D after DMEK was observed three months after surgery, which is in line with the mean astigmatism change of +0.31 D reported in the OTA.⁷ Consequently, DMEK can be considered a predictable and relatively refractive neutral

procedure that allows safe combination with cataract surgery and intraocular lens placement.^{17,18} Target refraction in triple DMEK was not captured by the registry. Cases that underwent triple DMEK were therefore excluded in the analysis of spherical equivalent and refractive shift.

In EK, most endothelial cell loss is registered early after transplantation. Three months postoperatively, mean cell loss measured 33%, stabilizing thereafter. The cell loss is in line with previous reports on DMEK,^{7,14,15} and comparable to the NOTR DSAEK cohort for FED.³

Graft detachment necessitating rebubbling is the Achilles heel of DMEK. In the literature, the percentage of eyes requiring rebubbling ranges from 2% to 84%,⁷ with most studies reporting percentages between 10% and 30%.^{14,15,19} In the current cohort, 19% of eyes required underwent rebubbling. The rebubbling protocols were not standardized across medical centers. NOTR does not capture details on the degree of graft detachment. However, most surgeons in the Netherlands perform rebubbling for graft detachments that are centrally located or affect more than 1/3 of the graft surface area. There is controversy in the literature regarding complication rates with triple procedure compared with DMEK alone.²⁰⁻²² In our cohort, there was no significant or clinically relevant difference in rebubbling rate between triple and single procedures. Sulfur hexafluoride (SF₆) at various concentrations can be used instead of 100% air to decrease graft detachment rate, because SF₆ has a longer tamponade time than 100% air. A recent meta-analysis reported that 20% SF₆ was associated with 58% fewer rebubbling procedures compared to 100% air.²³ However, this information was not captured prospectively by NOTR. Future registry studies could shed light on the effect of SF₆ in routine clinical practice.

Previous studies reported complication rates decrease over time as surgical experience increases.^{19,23,24} While overall graft survival improved over the study period, the incidence of rebubbling procedures increased. This may be due to consecutive learning curves of multiple surgeons

and/or more aggressive approach towards graft dislocation. However, in accordance with the institutional review board of NOTR, data for the current study was not stratified by surgeon or center.

The risk of an immunological rejection after DMEK is lower compared to previous keratoplasty techniques and often does not lead to graft failure.^{25–27} Moreover, the clinical picture of graft rejection after DMEK can be very subtle.²⁸ For prophylaxis, local corticosteroid therapy is recommended until at least the end of the second postoperative year.²⁶ In our cohort, patients received a tapered topical corticosteroid regimen during the first six months, followed by low dose maintenance and two patients developed graft rejection that was reversible following local steroid injection. From six months postoperatively onwards,

only six cases of graft failure occurred. The follow-up of the current cohort is insufficient to determine long-term rates of graft failure and rejection.

Every cohort study has to cope with missing data and loss to follow-up. With respect to our primary outcome, i.e. graft survival, centralized donor allocation by the Dutch Transplant Society (NTS) ensured registration of all primary- and repeated transplantations. With regard to secondary outcomes, LMM analysis uses all available data (no list-wise deletion that would only allow completers in the analyses). Almost all graft failures occurred prior to the first follow-up visit registered in NOTR, i.e. three months postoperatively, therefore, to increase the robustness of the data, graft failures were excluded from analyses of VA, ECD, and SE.

ALL AUTHORS HAVE COMPLETED AND SUBMITTED THE ICMJE FORM FOR DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST and none were reported.

Funding/Support: None.

Financial disclosures: R.M.M.A.N. is a consultant for Alcon, Asico, and ThéaPharma; and has received research support from Acufocus, Alcon, Bausch & Lomb, HumanOptics, and Ophtec; and has received lecture fees from Alcon. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

The authors thank Cynthia Konijn, Dutch Transplant Foundation, for processing data application and members of the Dutch Corneal Workgroup for their dedication and precise data registration.

The authors acknowledge the Dutch Cornea Consortium (excluding writing committee): Marjolijn C. Bartels, MD, PhD; Yanny Y. Cheng, MD, PhD; Bart T.H. van Dooren, MD, PhD; Cathrien A. Eggink, MD, PhD; Annette J.M. Geerards, MD; Tom A. van Goor, MD; Ype P. Henry, MD; Ruth Lapid-Gortzak, MD, PhD; Chantal M. van Luijk, MD; Ivanka J. van der Meulen, MD, PhD; Carla P. Nieuwendaal, MD; SiamakNobacht, MD; Monica T.P. Odenthal, MD, PhD; Lies Remeijer, MD, PhD; Jeroen van Rooij, MD; Nathalie T.Y. Santana, MD, PhD; Remco Stoutenbeek, MD, PhD; Mei L. Tang, MD; ThijsVaessen, MD; NienkeVisser, MD, PhD; Robert H.J. Wijdh, MD; Robert P.L. Wisse, MD, PhD; and Michel J.W. Zaal, MD, PhD.

REFERENCES

1. Lauer MS, D'Agostino RB Sr. The randomized registry trial—the next disruptive technology in clinical research? *N Engl J Med* 2013;369:1579–1581.
2. Sherman RE, Anderson SA, Dal Pan GJ, et al. Real-world evidence - what is it and what can it tell us? *N Engl J Med* 2016; 375:2293–2297.
3. Dickman MM, Peeters JM, van den Biggelaar FJ, et al. Changing practice patterns and long-term outcomes of endothelial versus penetrating keratoplasty: a prospective dutch registry study. *Am J Ophthalmol* 2016;170:133–142.
4. Dickman MM, Spekrijse LS, Dunker SL, et al. Long-term outcomes of repeated corneal transplantations: a prospective Dutch registry study. *Am J Ophthalmol* 2018;193:156–165.
5. Peraza-Nieves J, Baydoun L, Dapena I, et al. Two-year clinical outcome of 500 consecutive cases undergoing Descemet membrane endothelial keratoplasty. *Cornea* 2017;36: 655–660.
6. Melles GR, Lander F, Rietveld FJ. Transplantation of descemet's membrane carrying viable endothelium through a small scleral incision. *Cornea* 2002;21:415–418.
7. Deng SX, Lee WB, Hammersmith KM, et al. Descemet membrane endothelial keratoplasty: safety and outcomes: a report by the American Academy of Ophthalmology. *Ophthalmology* 2018;125:295–310.
8. van Rooij J, Lucas EH, Geerards AJ, Remeijer L, Wubbels R. Corneal transplantation for fuchs endothelial dystrophy: a comparison of three surgical techniques concerning 10 year graft survival and visual function. *PLoS One* 2018;13: e0203993.
9. van den Berg TJ, Franssen L, Coppens JE. Straylight in the human eye: testing objectivity and optical character of the psychophysical measurement. *Ophthalmic Physiol Opt* 2009; 29:345–350.
10. van der Meulen IJ, van Riet TC, Lapid-Gortzak R, Nieuwendaal CP, van den Berg TJ. Correlation of straylight and visual acuity in long-term follow-up of manual descemet stripping endothelial keratoplasty. *Cornea* 2012; 31:380–386.
11. van der Meulen IJ, Patel SV, Lapid-Gortzak R, Nieuwendaal CP, McLaren JW, van den Berg TJ. Quality of vision in patients with fuchs endothelial dystrophy and after descemet stripping endothelial keratoplasty. *Arch Ophthalmol* 2011;129:1537–1542.
12. Wacker K, Baratz KH, Bourne WM, Patel SV. Patient-reported visual disability in Fuchs' endothelial corneal dystrophy measured by the visual function and corneal health status instrument. *Ophthalmology* 2018;125:1854–1861.
13. Claesson M, Armitage WJ, Bystrom B, et al. Validation of catquest-9SF-avisual disability instrument to evaluate patient function after corneal transplantation. *Cornea* 2017;36: 1083–1088.
14. Chamberlain W, Lin CC, Austin A, et al. Descemet endothelial thickness comparison trial: a randomized trial comparing ultrathin Descemet stripping automated endothelial keratoplasty with Descemet membrane endothelial keratoplasty. *Ophthalmology* 2019;126:19–26.

15. Dunker SL, Dickman MM, Wisse RPL, et al. Descemet membrane endothelial keratoplasty versus ultrathin descemet stripping automated endothelial keratoplasty: a multicenter randomized controlled clinical trial. *Ophthalmology* 2020; 127:1152–1159.
16. Scorgia V, Matteoni S, Scorgia GB, Scorgia G, Busin M. Pentacam assessment of posterior lamellar grafts to explain hyperopization after Descemet's stripping automated endothelial keratoplasty. *Ophthalmology* 2009;116:1651–1655.
17. Schoenberg ED, Price FW Jr, Miller J, McKee Y, Price MO. Refractive outcomes of Descemet membrane endothelial keratoplasty triple procedures (combined with cataract surgery). *J Cataract Refract Surg* 2015;41:1182–1189.
18. Chaurasia S, Price FW Jr, Gunderson L, Price MO. Descemet's membrane endothelial keratoplasty: clinical results of single versus triple procedures (combined with cataract surgery). *Ophthalmology* 2014;121:454–458.
19. Oellerich S, Baydoun L, Peraza-Nieves J, et al. Multicenter study of 6-month clinical outcomes after Descemet membrane endothelial keratoplasty. *Cornea* 2017;36: 1467–1476.
20. Leon P, Parekh M, Nahum Y, et al. Factors associated with early graft detachment in primary Descemet membrane endothelial keratoplasty. *Am J Ophthalmol* 2018; 187:117–124.
21. Siebelmann S, Ramos SL, Matthaei M, et al. Factors associated with early graft detachment in primary Descemet membrane endothelial keratoplasty. *Am J Ophthalmol* 2018;192: 249–250.
22. Godin MR, Boehlke CS, Kim T, Gupta PK. Influence of lens status on outcomes of Descemet membrane endothelial keratoplasty. *Cornea* 2019;38:409–412.
23. Schrittenlocher S, Schaub F, Hos D, Siebelmann S, Cursiefen C, Bachmann B. Evolution of consecutive Descemet membrane endothelial keratoplasty outcomes throughout a 5-year period performed by two experienced surgeons. *Am J Ophthalmol* 2018;190:171–178.
24. Dapena I, Ham L, Droutsas K, van Dijk K, Moutsouris K, Melles GR. Learning curve in Descemet's membrane endothelial keratoplasty: first series of 135 consecutive cases. *Ophthalmology* 2011;118:2147–2154.
25. Hos D, Tuac O, Schaub F, et al. Incidence and clinical course of immune reactions after Descemet membrane endothelial keratoplasty: retrospective analysis of 1000 consecutive eyes. *Ophthalmology* 2017;124:512–518.
26. Price MO, Scanameo A, Feng MT, Price FW Jr. Descemet's membrane endothelial keratoplasty: risk of immunologic rejection episodes after discontinuing topical corticosteroids. *Ophthalmology* 2016;123:1232–1236.
27. Price MO, Price FW Jr, Kruse FE, Bachmann BO, Tourtas T. Randomized comparison of topical prednisolone acetate 1% versus fluorometholone 0.1% in the first year after Descemet membrane endothelial keratoplasty. *Cornea* 2014;33: 880–886.
28. Hos D, Matthaei M, Bock F, et al. Immune reactions after modern lamellar (DALK, DSAEK, DMEK) versus conventional penetrating corneal transplantation. *Prog Retin Eye Res* 2019;73:100768.